Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?

The oncologist

Volumn 15 Suppl 4, Issue , 2010, Pages 42-52

  Lencioni, Riccardo ^a   Chen, Xiao Ping ^b   Dagher, Lucy ^b   Venook, Alan P ^b  

^a UNIVERSITY OF PISA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE; SORAFENIB;

CANCER STAGING; CHEMOEMBOLIZATION; HEALTH CARE QUALITY; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; PALLIATIVE THERAPY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; PALLIATIVE CARE; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STANDARD OF CARE; TREATMENT OUTCOME;

EID: 79952277001     PISSN: None     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-S4-42     Document Type: Review

References (0)